Access Biotechnology

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers across all ages, with an initial emphasis on pediatric patients. The company aims to bring effective cancer treatments to families by advancing therapies that can benefit both children and adults, prioritizing programs that can progress to the market rapidly. Day One pursues licensing or acquisition of promising products from research institutions and industry partners to expand its pipeline. Its lead candidate, DAY101, is an oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target cancers driven by the RAF signaling pathway. By applying insights from childhood cancer biology, the company seeks to address unmet needs in oncology and broaden access to precision therapies.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Santa Ana Bio is a biotechnology company focused on developing precision biologics for autoimmune and inflammatory diseases. The company employs advanced technologies, including deep cell profiling, multi-omics platforms, and single-cell genomics, to create targeted therapies. By utilizing antibody engineering and sophisticated analytics, Santa Ana Bio aims to deliver personalized treatments that enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Zura Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for immune and inflammatory disorders. It focuses on advancing its pipeline of treatments through phase 2 development programs, including ZB-168 and torudokimab, which target autoimmune illnesses. ZB-168 is an anti-IL7R inhibitor designed to address disorders linked to IL7 and TSLP biological pathways, building on encouraging phase 1b data related to type 1 diabetes. Torudokimab, a human-affinity monoclonal antibody, is in phase 2 clinical development and works by neutralizing IL33. Through these initiatives, Zura Bio aims to create effective therapeutic options for patients suffering from complex immune-related conditions.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Recludix Pharma develops a platform for discovering potent and selective inhibitors of complex protein targets. The platform integrates custom-generated DNA-encoded libraries, massively parallel structure-activity relationship determination, and proprietary screening tools to ensure selectivity.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Perfuse Therapeutics is a biotechnology company dedicated to developing innovative therapies for eye diseases. The firm is focused on a novel mechanism aimed at improving retinal perfusion, which is crucial for addressing various retinal conditions. Initially targeting glaucoma, Perfuse Therapeutics aims to enhance blood flow to the retina, thereby enabling healthcare professionals to slow the progression of diseases such as non-proliferative diabetic retinopathy and retinal vein occlusion. Through its research and development efforts, the company seeks to offer effective treatment options that can significantly impact patient outcomes in the field of ophthalmology.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers across all ages, with an initial emphasis on pediatric patients. The company aims to bring effective cancer treatments to families by advancing therapies that can benefit both children and adults, prioritizing programs that can progress to the market rapidly. Day One pursues licensing or acquisition of promising products from research institutions and industry partners to expand its pipeline. Its lead candidate, DAY101, is an oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target cancers driven by the RAF signaling pathway. By applying insights from childhood cancer biology, the company seeks to address unmet needs in oncology and broaden access to precision therapies.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.